Inhibrx Future Growth
Future criteria checks 0/6
Inhibrx se prevé un crecimiento anual de los beneficios y los ingresos de 10.3% y 67%, respectivamente, mientras que el BPA aumentará de grow a 16.5%.
Key information
25.5%
Earnings growth rate
28.5%
EPS growth rate
| Biotechs earnings growth | 20.9% |
| Revenue growth rate | 60.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 29 Feb 2024 |
Recent future growth updates
Recent updates
Inhibrx down 8% after announcing webcast for pathway for rare disease candidate
Oct 03Inhibrx: Potential To Move To Registration Study With INBRX-101
Jun 10Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate
Mar 23
Analysts Are Updating Their Inhibrx, Inc. (NASDAQ:INBX) Estimates After Its First-Quarter Results
May 16What Percentage Of Inhibrx, Inc. (NASDAQ:INBX) Shares Do Insiders Own?
Jan 14Inhibrx's INBRX-109 wins FDA's Fast Track status
Jan 13Inhibrx reports data from dose escalation part of early-stage INBRX-106 trial in solid tumors
Jan 05Need To Know: Analysts Are Much More Bullish On Inhibrx, Inc. (NASDAQ:INBX) Revenues
Nov 22Inhibrx EPS misses by $0.07
Nov 13Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 122 | -181 | N/A | N/A | 1 |
| 12/31/2025 | 2 | -252 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -199 | N/A | N/A | 1 |
| 12/31/2023 | 2 | -241 | -198 | -193 | N/A |
| 9/30/2023 | 0 | -189 | -169 | -167 | N/A |
| 6/30/2023 | 1 | -172 | -144 | -144 | N/A |
| 3/31/2023 | 1 | -163 | -129 | -128 | N/A |
| 12/31/2022 | 2 | -145 | -116 | -115 | N/A |
| 9/30/2022 | 5 | -125 | -108 | -107 | N/A |
| 6/30/2022 | 7 | -111 | -91 | -90 | N/A |
| 3/31/2022 | 7 | -94 | -87 | -86 | N/A |
| 12/31/2021 | 7 | -82 | -81 | -80 | N/A |
| 9/30/2021 | 7 | -78 | -74 | -73 | N/A |
| 6/30/2021 | 11 | -78 | -75 | -73 | N/A |
| 3/31/2021 | 13 | -75 | -64 | -62 | N/A |
| 12/31/2020 | 13 | -76 | -49 | -48 | N/A |
| 9/30/2020 | 10 | -75 | -46 | -45 | N/A |
| 6/30/2020 | 6 | -74 | -33 | -31 | N/A |
| 3/31/2020 | 6 | -68 | -36 | -34 | N/A |
| 12/31/2019 | 13 | -51 | -34 | -32 | N/A |
| 9/30/2019 | 15 | -40 | -29 | -27 | N/A |
| 6/30/2019 | 15 | -30 | -29 | -27 | N/A |
| 3/31/2019 | 14 | -26 | -28 | -27 | N/A |
| 12/31/2018 | 9 | -31 | -25 | -23 | N/A |
| 9/30/2018 | 7 | -35 | -24 | -23 | N/A |
| 12/31/2017 | 8 | -19 | -20 | -19 | N/A |
| 12/31/2016 | 7 | -8 | N/A | -18 | N/A |
Analyst Future Growth Forecasts
Ingresos vs. tasa de ahorro: INBX se prevé que siga sin ser rentable en los próximos 3 años.
Beneficios frente mercado: INBX se prevé que siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: INBX se prevé que siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: INBX no tendrá ingresos el año que viene.
Ingresos de alto crecimiento: INBX no tendrá ingresos el año que viene.
Earnings per Share Growth Forecasts
Future Return on Equity
Futura rentabilidad financiera (ROE): Datos insuficientes para determinar si la Rentabilidad de los fondos propios de INBX se prevé elevada dentro de 3 años.